Loading...
•
Mar 31, 2020
Wave Life Sciences Q1 2020 Earnings Report
Wave Life Sciences reported financial results for Q1 2020 and provided a business update.
Key Takeaways
Wave Life Sciences reported a net loss of $47.5 million in the first quarter of 2020, compared to a net loss of $44.2 million in the same period of 2019. The company's research and development expenses were $41.2 million, and general and administrative expenses were $13.0 million. Wave ended the quarter with $120.9 million in cash and cash equivalents.
Data from both PRECISION-HD clinical trials expected in 2H 2020
Advancing clinical neurology pipeline – SNP3 and C9orf72 programs on track to initiate clinical development in 2H 2020
First ADAR-mediated RNA-editing data in non-human primates demonstrates editing efficiencies of up to 50%
Wave expects to share additional in vivo ADAR-mediated RNA-editing data and to announce its first RNA-editing program in 2020.
Forward Guidance
Wave expects that its existing cash and cash equivalents, together with expected and committed cash from its existing collaboration, will enable Wave to fund its operating and capital expenditure requirements into the third quarter of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...